Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy

NCT01290744

Borderline Lepromatous Leprosy Lepromatous Leprosy

COMPLETED PHASE4

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

NCT01595997

Mild-to-moderate Psoriasis Vulgaris

COMPLETED PHASE1/PHASE2

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

NCT01041625

Lichen Planus

UNKNOWN PHASE2

Ciclosporin in the Management of New Erythema Nodosum Leprosum

NCT00919542

Leprosy

COMPLETED PHASE2

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

NCT01714544

Psoriasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leprosy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clofazamine

clofazamine 50mg po qday (duration varies according to physician)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Known or suspected leprosy confirmed by skin biopsy and/or slit skin smears.
* Multibacillary leprosy (lepromatous leprosy or borderline-lepromatous).
* Paucibacillary leprosy (borderline, borderline tuberculoid, or indeterminate) if there is involvement of the cranial nerves or active acute neuritis.
* Known or suspected ENL(erythema nodosum leprosum) (a specific immune reaction with painful skin nodules and fever)
* Known or suspected dapsone-resistant leprosy or relapsed leprosy.
* Intolerance of other antileprosy antibiotic (where clofazamine is substituted as apart of multidrug regimen)

Exclusion Criteria

* Uncomplicated paucibacillary leprosy which would otherwise be treated with dapsone and rifampin only.
* Known prior intolerance of Clofazamine
* Any minor (even with parental consent)
* Any fertile woman who is pregnant a specific immune reaction with painful skin rash and fever)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No